Finerenone: all 73 studies that test it
Page 1 of 1. Open to participants first (41), then studies with results posted, then the rest; newest registration first within each.
- Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With AlbuminuriaNot yet recruitingNCT07849348Not applicable
- Finerenone and Cardiac Remodeling in HFpEFNot yet recruitingNCT07830940Phase 4
- Finerenone for Premature Ovarian Insufficiency (POI)Not yet recruitingNCT07815509Phase 2
- Finerenone After Catheter Ablation to Reduce Atrial Fibrillation RecurrenceRecruitingNCT07799519Phase 2
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNot yet recruitingNCT07775846Phase 4
- Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot TrialNot yet recruitingNCT07775482Not applicable
- Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary AldosteronismRecruitingNCT07688928Not applicable
- Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled TrialNot yet recruitingNCT07678151Not applicable
- Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney DiseaseNot yet recruitingNCT07667517Phase 4
- "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"Not yet recruitingNCT07598864Phase 3
- Precision T1D Platform - New Therapies for Cardio-Renal ComplicationsNot yet recruitingNCT07594145Phase 2
- Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.Not yet recruitingNCT07585526Not applicable
- Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF PatientsNot yet recruitingNCT07583173Phase 4
- Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart FailureRecruitingNCT07575672Phase 3
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationNCT07547878Phase 4
- Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety StudyNot yet recruitingNCT07523867Phase 4
- Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart FailureEnrolling by invitationNCT07442448Phase 4
- Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart FailureRecruitingNCT07397650Phase 4
- Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart FailureNot yet recruitingNCT07326631Not applicable
- Finerenone and Cardiac RemodelingNot yet recruitingNCT07270367Phase 3
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney DiseaseRecruitingNCT07239570Phase 4
- Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney DiseaseNot yet recruitingNCT07235891Phase 4
- A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic DysfunctionRecruitingNCT07192952Phase 3
- A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic DysfunctionRecruitingNCT07188805Phase 3
- FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system InhibitorsEnrolling by invitationNCT07181135Phase 3
- Role of Finerenone in African American Veterans With Diabetic Kidney DiseaseNot yet recruitingNCT07155694Phase 4
- Finerenone in Patients With IgA-nephropathy: Prospective Interventional TrialRecruitingNCT07056595Not applicable
- Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.RecruitingNCT07026539Phase 4
- Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility StudyEnrolling by invitationNCT06954090Phase 4
- Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN StudyRecruitingNCT06906081Phase 2
- Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney DiseaseRecruitingNCT06727409Phase 4
- Effect of Finerenone in IgA NephropathyNot yet recruitingNCT06580288Phase 3
- Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary AldosteronismNot yet recruitingNCT06164379Phase 4
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesRecruitingNCT06082063Phase 3
- The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR StudyRecruitingNCT06059664Phase 2
- The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectRecruitingNCT06058585Phase 3
- A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor AntagonistsRecruitingNCT06033950Phase 3
- A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)RecruitingNCT06024746Phase 3
- A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsRecruitingNCT06008197Phase 3
- Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary AldosteronismNot yet recruitingNCT05814770Phase 4
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaRecruitingNCT05457283Phase 3
- A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 DiabetesCompletedNCT05254002Phase 2Results posted
- An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD ParticipantsCompletedNCT05013008Phase 2Results posted
- Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%CompletedNCT04435626Phase 3Results posted
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney DiseaseCompletedNCT02545049Phase 3Results posted
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseaseCompletedNCT02540993Phase 3Results posted
- Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic NephropathyCompletedNCT01874431Phase 2Results posted
- Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease AloneCompletedNCT01807221Phase 2Results posted
- Optimizing Albuminuria Treatment in CKD With Finerenone and SemaglutideCompletedNCT07819227Phase 2
- Finerenone Plus SGLT2 Inhibitors in Heart FailureActive, not recruitingNCT07351864Phase 4
- A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male ParticipantsCompletedNCT07116512Phase 1
- Effect of Finerenone in Patients With Non-diabetic GlomerulonephritisCompletedNCT06835322Phase 2
- Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCTTerminatedNCT06818305Phase 2
- Finerenone for Patients With Primary Aldosteronism (FAIRY)CompletedNCT06457074Phase 4
- The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary AldosteronismCompletedNCT06381323Phase 4
- Finerenone and Renal Oxidative StressCompletedNCT06244758Phase 3
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical TrialCompletedNCT06094920Phase 4
- Efficacy and Safety of Finerenone in Patients With Primary AldosteronismCompletedNCT05924620Phase 4
- A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 DiabetesCompletedNCT05901831Phase 3
- Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)Active, not recruitingNCT05887817Phase 4
- A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes MellitusCompletedNCT05705271Phase 4
- A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaActive, not recruitingNCT05196035Phase 3
- A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney DiseaseCompletedNCT05047263Phase 3
- A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender DistributionCompletedNCT04908436Phase 1
- A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender DistributionCompletedNCT04881994Phase 1
- A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)CompletedNCT04795726Not applicable
- Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male SubjectsCompletedNCT02957396Phase 1
- Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male VolunteersCompletedNCT02956109Phase 1
- Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)CompletedNCT01968668Phase 2
- Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease AloneCompletedNCT01955694Phase 2
- Dose Proportionality Study With BAY94-8862 IR (Immediate Release) TabletsCompletedNCT01687920Phase 1
- Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862CompletedNCT01473108Phase 1
- BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney DiseaseCompletedNCT01345656Phase 2